lystn

This episode of the Business of Biotech is fire. In fact, it's an interview with SalioGen Therapeutics Chairman and CEO Ray Tabibiazar, M.D.,, whose last name literally translates to "Dr. Fire."  Learn how he got that name, what's shaped his technology-agnostic philosophy on therapeutic development,  the advantages of a genome engineering technology that leverages proprietary mammal-derived enzymes, rather than viruses, and how SalioGen is possibly carrying forth a pipeline that's 15 candidates deep and addressing eye, liver, heart, lung, bone marrow, and kidney diseases.

Learn more about gene therapy validation strategies at bioprocessonline.com.